Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer. Issue 5 (7th February 2020)

• Record Type: Journal Article
• Authors: Corrales‐Sánchez, Verónica; Noblejas‐López, María del Mar; Nieto‐Jiménez, Cristina; Pérez‐Peña, Javier; Montero, Juan Carlos; Burgos, Miguel; Galán‐Moya, Eva M.; Pandiella, Atanasio; Ocaña, Alberto
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 5(2020)
• Page Start: 3117
• Page End: 3127
• Publication Date: 2020-02-07
• Subjects: breast cancer -- dasatinib -- olaparib -- screening -- triple negative; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14980
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Identification of druggable vulnerabilities is a main objective in triple‐negative breast cancer (TNBC), where no curative therapies exist. Gene set enrichment analyses (GSEA) and a pharmacological evaluation using a library of compounds were used to select potential druggable combinations. MTT and studies with semi‐solid media were performed to explore the activity of the combinations. TNBC cell lines (MDAMB‐231, BT549, HS‐578T and HCC3153) and an additional panel of 16 cell lines were used to assess the activity of the two compounds. Flow cytometry experiments and biochemical studies were also performed to explore the mechanism of action. GSEA were performed using several data sets (GSE21422, GSE26910, GSE3744, GSE65194 and GSE42568), and more than 35 compounds against the identified functions were evaluated to discover druggable opportunities. Analyses done with the Chou and Talalay algorithm confirmed the synergy of dasatinib and olaparib. The combination of both agents significantly induced apoptosis in a caspase‐dependent manner and revealed a pleotropic effect on cell cycle: Dasatinib arrested cells in G0/G1 and olaparib in G2/M. Dasatinib inhibited pChk1 and induced DNA damage measured by pH2AX, and olaparib increased pH3. Finally, the effect of the combination was also evaluated in a panel of 18 cell lines representative of the most frequent solid tumours, observing a particularly synergism in ovarian cancer. Breast cancer, triple negative, dasatinib, olaparib, screening.